QFR vs FFR-guided PCI: The FAVOR III Europe Trial
The FAVOR III Europe trial demonstrated that a QFR-guided strategy did not meet the non-inferiority criteria for 1-year MACE (including all-cause mortality, myocardial infarction (MI), and unplanned revascularization) compared to the FFR-guided strategy in patients with intermediate coronary artery stenosis, according to a study presented by Dr. Birgitte Krogsgaard Andersen, Aarhus University, Denmark, in the Late-Breaking Clinical Trials session at TCT 2024.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.